Fiche publication
Date publication
mai 2004
Auteurs
Membres identifiés du Cancéropôle Est :
Pr CHENARD Marie-Pierre
,
Dr TOMASETTO Catherine
Tous les auteurs :
Chenard MP, Tomasetto C, Bellocq JP, Rio MC
Lien Pubmed
Résumé
pS2/TFF1 overexpression in breast carcinomas correlates with response to hormonotherapy. We evaluated the clinical relevance of urinary pS2/TFF1 in breast cancer patients. In healthy controls (100 cases), it represents an individual and relatively stable parameter. Although 24 out 83 pre-operative breast cancer patients showed elevated levels, both the sensitivity and specificity of the test were too low for breast cancer screening. However, neoadjuvant hormonotherapy decreased pS2/TFF1 levels in nine out of 20 patients. Furthermore, among 22 patients receiving long-term adjuvant hormonotherapy, four exhibited elevated levels, two of them at the time of relapse. Thus, urinary pS2/TFF1 quantification might be suitable as an in vivo diagnosis for tumor hormonodependency, and disease follow-up during hormonotherapy.
Référence
Peptides. 2004 May;25(5):737-43.
